BioCentury | Nov 21, 2016
Strategy

LG’s biotech legacy

LG Life Sciences Ltd. was a pioneer, producing the first globally approved drugs developed by a South Korean company. A shift in priorities all but stopped the flow of innovative new drugs to the world...
BC Week In Review | Nov 18, 2016
Company News

LG Life Sciences, LG Chem deal

In September, LG Corp. (KSE:003550, Seoul, South Korea) affiliates LG Life Sciences and LG Chem said they would merge in a stock deal, with the latter remaining as the surviving entity. The deal is expected...
BC Week In Review | Mar 12, 2012
Company News

Cornerstone Therapeutics, Merus Labs International sales and marketing update

Merus acquired North American rights to Factive gemifloxacin mesylate from Cornerstone. Cornerstone will receive an undisclosed payment from Merus. Cornerstone said in its 2011 10-K that it is moving away from primary care due to...
BioCentury | Mar 12, 2012
Finance

Argos plowing ahead

Argos Therapeutics Inc. is being coy about its financing plans after withdrawing its planned IPO on NASDAQ due to market conditions. But the company says it is going ahead next quarter with a $40-$50 million...
BC Week In Review | Mar 21, 2011
Clinical News

Avelox moxifloxacin regulatory update

FDA updated the labels for antimicrobial fluoroquinolones to include a boxed warning that the drugs may exacerbate muscle weakness in patients with myasthenia gravis. The agency said that postmarketing adverse events, including deaths and the...
BioCentury | Oct 5, 2009
Finance

Restructuring Watch

Restructuring Watch Date Company Staff cuts Cash Years cash pre-cut Cash date 1H09 oper loss 7/1/09 CombinatoRx Inc. (NASDAQ:CRXX) 36% to ~35 $26.5 0.84 6/30/09 $15.8 Restructures in connection with its merger with Neuromed Pharmaceuticals...
BC Week In Review | Sep 7, 2009
Company News

Cornerstone Therapeutics, Oscient deal

Cornerstone said the U.S. Bankruptcy Court for the District of Massachusetts approved its previously announced acquisition of Factive gemifloxacin mesylate from Oscient. The deal will close "promptly." Oscient filed for Chapter 11 in July (see...
BC Week In Review | Jul 20, 2009
Company News

Cornerstone Therapeutics, Oscient deal

On July 13, Oscient filed Chapter 11 Bankruptcy and said it plans to sell to Cornerstone its assets related to Factive gemifloxacin mesylate. Oscient will receive $5 million, plus the value of its Factive inventory...
BioCentury | Jul 6, 2009
Finance

Restructuring Watch

Restructuring Watch Date Company Staff cuts Cash Years cash pre-cut Cash date Oper loss for 3 mos ended 3/31 4/2/09 Vermillion Inc. (Pink:VRMLQ) Not disclosed $1.9 0.13 9/30/08 $11 (A) Files for Chapter 11 bankruptcy;...
BC Week In Review | Jun 29, 2009
Clinical News

Factive gemifloxacin mesylate regulatory update

Menarini said it withdrew an MAA for Factive gemifloxacin to treat mild to moderate community-acquired pneumonia (CAP) and acute exacerbation of chronic bronchitis. The company said it withdrew the application after EMEA's CHMP indicated that...
Items per page:
1 - 10 of 120